- Home
- LCTX vs GCTS Comparison
LCTX vs GCTS Comparison
Compare LCTX & GCTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCTX
- GCTS
- Stock Information
- Founded
- LCTX 1990
- GCTS 1998
- Country
- LCTX United States
- GCTS United States
- Employees
- LCTX N/A
- GCTS N/A
- Industry
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- GCTS Blank Checks
- Sector
- LCTX Health Care
- GCTS Finance
- Exchange
- LCTX Nasdaq
- GCTS Nasdaq
- Market Cap
- LCTX 127.7M
- GCTS 102.6M
- IPO Year
- LCTX N/A
- GCTS N/A
- Fundamental
- Price
- LCTX $0.68
- GCTS $2.02
- Analyst Decision
- LCTX Strong Buy
- GCTS Strong Buy
- Analyst Count
- LCTX 4
- GCTS 1
- Target Price
- LCTX $4.50
- GCTS $5.00
- AVG Volume (30 Days)
- LCTX 1.2M
- GCTS 116.8K
- Earning Date
- LCTX 03-06-2025
- GCTS 04-03-2025
- Dividend Yield
- LCTX N/A
- GCTS N/A
- EPS Growth
- LCTX N/A
- GCTS N/A
- EPS
- LCTX N/A
- GCTS N/A
- Revenue
- LCTX $8,719,000.00
- GCTS $11,532,000.00
- Revenue This Year
- LCTX N/A
- GCTS N/A
- Revenue Next Year
- LCTX $41.15
- GCTS $463.17
- P/E Ratio
- LCTX N/A
- GCTS N/A
- Revenue Growth
- LCTX N/A
- GCTS N/A
- 52 Week Low
- LCTX $0.48
- GCTS $1.97
- 52 Week High
- LCTX $1.61
- GCTS $56.00
- Technical
- Relative Strength Index (RSI)
- LCTX 53.39
- GCTS 40.86
- Support Level
- LCTX $0.58
- GCTS $1.97
- Resistance Level
- LCTX $0.73
- GCTS $2.36
- Average True Range (ATR)
- LCTX 0.05
- GCTS 0.14
- MACD
- LCTX 0.00
- GCTS 0.00
- Stochastic Oscillator
- LCTX 50.67
- GCTS 13.92
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
About GCTS GCT Semiconductor Holding Inc. Common Stock
GCT Semiconductor Holding Inc. is a designer and supplier of 5G and 4G LTE semiconductor solutions. It enabled fast and reliable 4G LTE connectivity to numerous commercial devices such as CPEs, mobile hotspots, routers, M2M applications and smartphones, etc. The system-on-chip solutions integrate radio frequency, baseband modem and digital signal processing functions, therefore offering complete 4G and 5G platform solutions with small form factors, low power consumption, high performance, high reliability, and cost-effectiveness.